| 5.54 0.07 (1.28%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.96 | 1-year : | 8.13 |
| Resists | First : | 5.96 | Second : | 6.96 |
| Pivot price | 5.2 |
|||
| Supports | First : | 4.88 | Second : | 4.22 |
| MAs | MA(5) : | 5.31 |
MA(20) : | 5.06 |
| MA(100) : | 3.54 |
MA(250) : | 2.31 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 61.5 |
D(3) : | 53.9 |
| RSI | RSI(14): 65.1 |
|||
| 52-week | High : | 5.96 | Low : | 1.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATAI ] has closed below upper band by 20.8%. Bollinger Bands are 14% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.7 - 5.72 | 5.72 - 5.75 |
| Low: | 5.33 - 5.35 | 5.35 - 5.37 |
| Close: | 5.5 - 5.54 | 5.54 - 5.58 |
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Wed, 01 Oct 2025
Atai Life Sciences: Still A Decent Prospect - But Only Just (NASDAQ:ATAI) - Seeking Alpha
Mon, 29 Sep 2025
ATAI Life Sciences files additional details on Beckley Psytech acquisition - Investing.com
Wed, 24 Sep 2025
atai Life Sciences stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Tue, 23 Sep 2025
Atai Life Sciences N.V. (ATAI) Advances Psychedelic Therapies for Mental Health, Drawing Investor Spotlight - Yahoo Finance
Tue, 23 Sep 2025
atai Life Sciences rises after promising data from depression trial - Seeking Alpha
Sat, 20 Sep 2025
H.C. Wainwright Affirms ‘Buy’ Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 234 (M) |
| Held by Insiders | 1.1637e+008 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 15,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.485e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 515 % |
| Return on Equity (ttm) | -29.6 % |
| Qtrly Rev. Growth | 2.31e+006 % |
| Gross Profit (p.s.) | 102.76 |
| Sales Per Share | -48.12 |
| EBITDA (p.s.) | 1.45283e+006 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -76 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.12 |
| Price to Cash Flow | 12.95 |
| Dividend | 0 |
| Forward Dividend | 1.779e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|